Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report

Frontiers in Oncology

Oncology

Yuxian Liang¹  Jiayu Zheng¹  Qingyun Pan¹  Quanfang Chen¹  Lingxin Yan¹  Pengli Yu² 

[1] Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;Geneplus-Beijing Institute, Beijing, China;

关键词: PPFIA1-ALK;    alectinib;    NSCLC;    NGS;    non-reciprocal fusion;   

DOI  :  10.3389/fonc.2023.1264820

 received in 2023-07-21, accepted in 2023-08-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

Non-small cell lung cancers (NSCLCs) with anaplastic lymphoma kinase (ALK)-rearrangement have favorable responses to ALK inhibitors. However, ALK fusion mutations harbored approximately 90 distinct fusion partners. Patients with different ALK fusions might respond distinctly to different-generation ALK inhibitors. In this case report, we identified a novel non-reciprocal ALK fusion, ALK-C2orf91(intergenic) (A19: intergenic) and PPFIA1-ALK (P2:A20), by next-generation DNA sequencing in an advanced lung adenocarcinoma patient. After 2 months of alectinib, the targeted lung lesion regressed significantly, and evaluation of therapeutic efficiency indicated partial response. To date, the patient had achieved 12 months of progression-free survival from alectinib treatment. Our study extended the spectrum of ALK fusion partners in ALK-positive NSCLC, and we reported a new ALK fusion, PPFIA1-ALK and ALK-C2orf91(intergenic), and its sensitivity to alectinib firstly in lung cancer. We believe that this case report has an important clinical reference.

【 授权许可】

Unknown   
Copyright © 2023 Yan, Zheng, Pan, Liang, Yu and Chen